Introduction
Although inappropriate or pathological anxiety is generally accepted as a major cause of psychiatric morbidity, the separate designation of Panic Disorder is relatively recent [1] . The syndrome is characterised by repeated, brief episodes of intense fear, feelings of impending doom and a host of physical symptoms. Since Panic Disorder was recognised as a distinct diagnostic entity in 1980 by the American Psychiatric Association (DSM-III) it has become a focus of increasing attention in the psychiatric literature and a target for pharmacological interventions. The benzodiazepine alprazolam has recently been approved for this indication in the United States and there is evidence that other benzodiazepines, as well as antidepressants, are effective treatments [2] .
The unpredictability of spontaneous panic attacks has led investigators to examine alternative models of panic in vulnerable patients. These have included the response to a number of pharmacological challenges such as sodium lactate, carbon dioxide, yohimbine [3] and, more recently, the cholecystokinin (CCK) fragment CCK-4. CCK is a peptide which is thought to act as a neurotransmitter or neuromodulator in the mammalian nervous system. Two pharmacologically distinct CCK receptors have been identified; the CCKA subtype predominates in peripheral tissues while the CCKB receptor (which is pharmacologically indistinguishable from the peripheral gastrin receptor) predominates within the brain [4] . It has been demonstrated that rapid intravenous injections of the CCKB/gastrin receptor agonists, CCK-4 and pentagastrin, reliably induce panic attacks in patients with Panic Disorder [5] [6] [7] . Pre-treatment with the CCKB receptor antagonist L-365,260 prevents panic attacks in this model [8] . These findings suggest that CCK might be implicated in the pathophysiology of Panic Disorder and indicate a possible novel therapeutic approach involving CCKB receptor antagonism.
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While much valuable information has been gleaned from pharmacological challenge models, the induction of panic attacks in vulnerable patients has significant ethical and practical limitations. Consequently, it would be desirable if a reliable model of Panic Disorder could be developed in normal volunteers. The aim would be to produce submaximal anxiety in normal subjects, rather than panic attacks, on the assumption that panic attacks lie at the extreme end of an anxiety continuum. In Study 1 we sought to develop such a model by investigating whether injections of pentagastrin in normal volunteers could induce symptoms typically found in panic attacks. In addition, a novel computerised rating system was used to allow continuous monitoring of anxiety levels.
Methods

Study I
The study was undertaken at Merck, Sharp and Dohme Neuroscience Research Centre, Terlings Park, Harlow, UK. The protocol was approved by the Terlings Park ethics committee and all subjects gave written informed consent.
Subjects
Sixteen subjects (11 males, 5 females), between the ages of 20 and 48 years, took part in the study. None of the subjects had previously received pentagastrin.
Design score over time curve (AUC) and maximum anxiety scores. Latency to onset, defined as time in seconds to the first non-zero rating (i.e. the time the subject first moved the mouse to rate anxiety) and latency to maximum score (i.e. time to peak anxiety) were also measured. For 10 subjects pulse rate data was recorded every 30 s by means of an ear lobe probe attached to a Solex PS300 pulse oximeter. The primary outcome measure was the maximum pulse rate. Immediately following the computerised anxiety rating, subjects were required to complete the Panic Symptoms Scale (PSS) [7] . This scale lists 24 symptoms commonly experienced by patients with Panic Disorder and subjects were required to rate symptom severity on a scale of 0 (not present) - The results from the PSS were similarly clear cut. Statistical analysis of mean PSS scores (Table 1) indicated a significant main effect of treatment and a significant linear dose trend which accounted for 99.8% of the total dose variation. Post-ANOVA testing indicated significant differences between all pairs of treatments. Mean severity ratings for the individual items of the PSS following the highest dose of pentagastrin vs placebo are shown in Table 2 . It can be seen that mean scores following pentagastrin were higher than those after placebo for all items except 'fear of going crazy'. The pentagastrin vs placebo difference was statistically significant for 16 of the 24 items, i.e.: 'abdominal distress', 'accelerated heart', 'feeling short of breath', 'apprehension', 'nausea', 'unsteady feeling', 'smothering sensation', 'palpitations', 'hot flushes', 'chest discomfort', 'choking feelings', 'numbness or tingling', 'dizziness', 'sweating', 'feeling detached from body' and 'shaking'.
Mean pulse rates at 30 s intervals over the 5 min test period for the 10 subjects in whom pulse rate recording was undertaken are shown in Figure 2 . All doses of pentagastrin resulted in increases in pulse rate but the dose-response relationship was less apparent than for subjective anxiety ratings, in that there appeared to be no difference between the two highest doses of pentagastrin. Statistical analysis of the maximum pulse rates (Table 1 ) confirmed this impression-there was a significant main effect of treatment and a significant linear dose trend which accounted for 87.8% of the total dose variation. [9] 2All pairwise comparisons significant (P < 0.05) except pentagastrin 0.3 gg kg-l vs pentagastrin 0.6 jg kg-l. 
Results
Study 2
Mean VAS anxiety ratings over the 10 Figure 4 . It can be seen that there was a similar pattern of results to that found for subjective anxiety ratings, in that pentagastrin produced an increase in pulse rate which appeared to be completely blocked by the 50 mg dose of L-365,260 and partially reversed by the 10 mg dose. Analysis of the maximum pulse rates (Table 4 ) indicated no significant pre-injection treatment differences. Postinjection, there was a significant treatment effect and planned contrasts indicated that only comparisons of placebo/pentagastrin vs the other treatments were significant (i.e. both doses of L-365,260 were equally effective in abolishing the pentagastrin induced increase in pulse rate).
The results for systolic and diastolic blood pressures ( Figure 5 ) were similar to each other. Analysis of the maximum scores (Table 4 ) indicated no significant pre-injection differences between any of the treatments for any measure. Post-injection, there were significant treatment effects in all cases. Planned contrasts showed that, for both measures, the only significant comparisons were for placebo/pentagastrin vs the other treatments, indicating that both doses of L-365,260 were equally effective in abolishing the increase in blood pressure produced by pentagastrin. (7) 123 (14) 39 (7) 16 (5) 14 ( 'Planned contrasts of placebo/pentagastrin vs other treatments significant (P < 0.05). 
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In this study subjective ratings and autonomic signs were measured for 5 min before as well as for 5 min after the pentagastrin injection. The aim of this experimental design was to determine whether subjects experienced a period of anticipatory anxiety which might allow an examination of any intrinsic anxiolytic properties of L-365,260 (as opposed to pentagastrin antagonism). It can be seen from Figure  3 that subjects did become somewhat more anxious as the injection approached. However, the increase was slight and probably not sufficient for any anxiolytic effects to be detected. Certainly, pretreatment with L-365,260 did not result in significantly different pre-injection subjective rating scores or autonomic changes compared with placebo. A similar pattern was found for pulse rates ( Figure  4 ). Systolic and diastolic blood pressures showed a slightly different pattern of results ( Figure 5 ). Both measures rose up to 30 s prior to the injection but then, following the sounding of the warning tone, fell quite sharply. This may be attributable to deep inspiration after the warning tone. The effect was apparent across all treatment groups and there was no indication of any differential response in those subjects pre-treated with L-365,260.
The continuous measurement of pulse and blood pressure in Study 2 allowed a detailed comparison of autonomic vs subjective anxiogenic effects of pentagastrin and anxiolytic effects of L-365,260. It can be seen from Figures 3, 4 and 5 that pentagastrin produced increases in subjective anxiety ratings, pulse rates and systolic and diastolic blood pressures which occurred simultaneously and had a similar duration. There was no evidence that L-365,260 had differential effects on autonomic vs affective components of anxiety. Although findings of temporal dissociations would have been of theoretical interest, it is important to note that the failure to distinguish autonomic and subjective events appears to be true of Panic Disorder itself [3, 10] . The present studies do not localise pentagastrin induced anxiety to either peripheral or central mechanisms. However, the latter are suggested by the observation that bolus injections of gastrin-17, a potent CCKB/gastrin receptor agonist which does not penetrate the blood-brain barrier, increases gastric acid secretion but does not have anxiogenic effects in man [11] .
The encouraging findings with L-365,260 in the present study are in contrast to recent results from a pilot, double-blind, placebo-controlled, 6 week, clinical trial of L-365,260 (30 mg four times daily) in 83 Panic Disorder patients which showed little evidence of efficacy [12] . However, interpretation of the data from this small trial is complicated by a number of factors, including the possibility of reduced compliance due to the fact that patients were required to ingest three capsules of L-365,260 four times each day (because of poor solubility). Even if such frequent dosing were adhered to, plasma levels associated with the blockade of CCK-4 induced panic would only have been maintained for a portion of the treatment period. Laboratory models have an advantage over clinical trials in this respect as compliance can be ensured, assessments can be timed to coincide with peak plasma levels, more detailed/accurate measurements can be undertaken and safety parameters can be carefully monitored so that it may be possible to administer higher doses of the test compound than would be considered prudent in an out-patient setting. Interestingly, a recent study which examined the effects of pre-treatment with L-365,260 50 mg on a sodium lactate challenge in Panic Disorder patients using the computer VAS system described here, did find some evidence of efficacy [13] . These findings are potentially important because the sodium lactate model is the best established procedure of its kind [14] and sodium lactate has no known direct influence on CCK neurotransmission. If these results are replicated in other models it may suggest that higher doses of L-365,260 than those investigated in the clinic to date, or other CCKB antagonists, could be effective in Panic Disorder.
In conclusion, injections of pentagastrin in normal volunteers result in brief periods of anxiety, the objective and subjective signs of which can be easily quantified. Pre-treatment with the CCKB antagonist L-365,260 blocks these anxiogenic effects. The pentagastrin model would appear to be a useful tool for the preliminary assessment of novel anxiolytic agents in normal volunteers.
